Small-Cell Lung Cancer: Integration of Radiation and Immunotherapy for All Stages
DOI:
https://doi.org/10.58931/cot.2025.2239Abstract
Small cell lung cancer is an aggressive cancer with a poor prognosis. New treatment paradigms have developed with the incorporation of new therapies in the last few years, aiming to improve patient survival. Some emerging therapies include the addition of immunotherapy to chemotherapy. This article provides a practical review of the current and upcoming treatment options for SCLC in both limited and extensive stages, focusing on integrating radiation and immunotherapy.
References
Lung Cancer Canada. 2024 Faces of lung cancer report [Internet]. Toronto (ON): Lung Cancer Canada; 2024 [cited Jun 22 2025].
Statistics Canada. Lung cancer is the leading cause of cancer death in Canada [Internet]. Ottawa (ON): Statistics Canada; 2022 Jan 4 [cited Jun 22 2025].
Früh M, Garassino MC, Dziadziuszko R, Peters S. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(Suppl 2):ii102–ii115.
Kalemkerian GP, Loo BW Jr, Akerley W, Attia A, Boumber Y, Decker RH, et al. Therapy for stage IV small-cell lung cancer: ASCO living clinical practice guideline. J Clin Oncol. 2023;41(30):3315–30.
Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265–71.
Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: JCOG 9104. J Clin Oncol. 2002;20(14):3054–60.
Auperin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999;341(7):476–84.
Chen, Y., Wang, Y., Ren, F. et al. Prophylactic cranial irradiation (PCI) versus active surveillance in patients with limited-stage small cell lung cancer: a retrospective, multicentre study. Respir Res 23, 274 (2022). https://doi.org/10.1186/s12931-022-02196-2.
Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, Zenke Y, et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. 2024;391(13):1313–1327. doi:10.1056/NEJMoa2404873.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–9. doi:10.1056/NEJMoa1809064.
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–39. doi:10.1016/S0140-6736(19)32222-6.
Paz-Ares L, Borghaei H, Liu SV, Peters S, Herbst RS, Stencel K, et al. Lurbinectedin plus atezolizumab as first-line maintenance therapy in extensive-stage small-cell lung cancer: primary results from the phase 3 IMforte trial. J Clin Oncol. 2025;43(Suppl 15):LBA8500. Presented at: ASCO Annual Meeting; 2025 Jun 2–6; Chicago, IL.
Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385(9962):36–42. doi:10.1016/S0140-6736(14)61085-0.
Slotman BJ, Faivre-Finn C, Kramer GWPM, Rankin EM, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664–72. doi:10.1056/NEJMoa071780.
Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663–71. doi:10.1016/S1470-2045(17)30110-1.
O’Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviă B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral or intravenous topotecan in patients with relapsed small-cell lung cancer. Lancet. 2004;364(9441):192–9. doi:10.1016/S0140-6736(04)16684-0.
von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658–67.
Rudin CM, Mountzios G, Sun L, Cho BC, Demirci U, Baka S, et al. Tarlatamab versus chemotherapy as second-line treatment for small cell lung cancer: primary analysis of the phase 3 DeLLphi-304 trial. J Clin Oncol. 2025;43(Suppl 17):LBA8008. doi:10.1200/JCO.2025.43.17_suppl.LBA8008.
Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063–75. doi:10.1056/NEJMoa2307980.
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Canadian Oncology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
